Perfusion Systems Market (Cardiopulmonary Perfusion, by Component (Heart-lung Machines, Oxygenators), Ex Vivo Organ Perfusion, Technique (Hypothermic, Normothermic), Cell Perfusion, by Type (Bioreactor, Microfluidic)) - Global Forecast to 2021
出 版 商：MarketsandMarkets
出版日期：2017/04/24
頁 數：154頁
文件格式：PDF
價 格：
USD 5,650 (Single-User License)
USD 6,650 (Multi-User License)
USD 8,150 (Global-User License)
USD 6,650 (Multi-User License)
USD 8,150 (Global-User License)
The perfusion systems market is projected to reach USD 1,198.8 million by 2021, at a CAGR of 3.9% during the forecast period 2016-2021. The growth of the market can be attributed to the increasing prevalence of cardiovascular and respiratory diseases, initiatives by governments and NGOs to encourage organ donation, increasing investment in cell-based research, and developments in biologics manufacturing.
The perfusion systems market is segmented on the basis of type (namely cardiopulmonary perfusion systems, ex vivo organ perfusion systems, and cell perfusion systems) and region. The global cardiopulmonary perfusion systems market is segmented based on components into oxygenators, heart-lung machines, perfusion pumps, cannulas, monitoring systems, and other components. While the oxygenators segment held the largest share of the global cardiopulmonary perfusion systems market in 2016, it is the perfusion pumps segment that is projected to grow at the highest CAGR during the forecast period.
The global cell perfusion systems market is segmented based on the type, as bioreactor perfusion systems, microfluidic perfusion systems, gravity or pressure-driven perfusion systems, and small-mammal organ perfusion systems. The bioreactor perfusion systems segment held the largest share of the market in 2016 and is also projected to register highest CAGR during the forecast period.
Based on technique, the ex vivo organ perfusion systems market is segmented into hypothermic machine perfusion and normothermic machine perfusion. The hypothermic machine perfusion segment accounted for the largest share of the market in 2016 and is also projected to grow at the highest CAGR during the forecast period.
On the basis of region, the global perfusion systems market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America held the largest share of the global market in 2016, followed by Europe.
The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, mainly due to the increasing aging population, rising organ donations and transplants in Japan, growth of the pharmaceutical and biotechnology R&D industry and CROs in China, and growing pharmaceutical & biotechnology industry and government initiatives in India.
Research Coverage:
The report studies factors affecting the growth of the perfusion systems market and analyzes opportunities and challenges in the market for stakeholders. It provides details of the competitive landscape of market leaders and analyzes micro-markets on their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market and help them garner a greater market share. Firms purchasing the report could use any one or a combination of the below mentioned strategies to strengthen their market shares.
The report provides insights on the following pointers:
‧ Market Penetration: Comprehensive information on the product portfolios of the top players in the perfusion systems market
‧ Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the perfusion systems market
‧ Market Development: Information about lucrative emerging markets. The report analyzes the markets for various perfusion products across regions
‧ Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the perfusion systems market
‧ Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the perfusion systems market
The perfusion systems market is segmented on the basis of type (namely cardiopulmonary perfusion systems, ex vivo organ perfusion systems, and cell perfusion systems) and region. The global cardiopulmonary perfusion systems market is segmented based on components into oxygenators, heart-lung machines, perfusion pumps, cannulas, monitoring systems, and other components. While the oxygenators segment held the largest share of the global cardiopulmonary perfusion systems market in 2016, it is the perfusion pumps segment that is projected to grow at the highest CAGR during the forecast period.
The global cell perfusion systems market is segmented based on the type, as bioreactor perfusion systems, microfluidic perfusion systems, gravity or pressure-driven perfusion systems, and small-mammal organ perfusion systems. The bioreactor perfusion systems segment held the largest share of the market in 2016 and is also projected to register highest CAGR during the forecast period.
Based on technique, the ex vivo organ perfusion systems market is segmented into hypothermic machine perfusion and normothermic machine perfusion. The hypothermic machine perfusion segment accounted for the largest share of the market in 2016 and is also projected to grow at the highest CAGR during the forecast period.
On the basis of region, the global perfusion systems market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America held the largest share of the global market in 2016, followed by Europe.
The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, mainly due to the increasing aging population, rising organ donations and transplants in Japan, growth of the pharmaceutical and biotechnology R&D industry and CROs in China, and growing pharmaceutical & biotechnology industry and government initiatives in India.
Research Coverage:
The report studies factors affecting the growth of the perfusion systems market and analyzes opportunities and challenges in the market for stakeholders. It provides details of the competitive landscape of market leaders and analyzes micro-markets on their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market and help them garner a greater market share. Firms purchasing the report could use any one or a combination of the below mentioned strategies to strengthen their market shares.
The report provides insights on the following pointers:
‧ Market Penetration: Comprehensive information on the product portfolios of the top players in the perfusion systems market
‧ Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the perfusion systems market
‧ Market Development: Information about lucrative emerging markets. The report analyzes the markets for various perfusion products across regions
‧ Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the perfusion systems market
‧ Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the perfusion systems market
TABLE OF CONTENTS
1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 17
1.3.1 MARKETS COVERED 17
1.3.2 YEARS CONSIDERED FOR THE STUDY 17
1.4 CURRENCY 18
1.5 LIMITATIONS 18
1.6 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH METHODOLOGY STEPS 19
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 20
2.2.1 SECONDARY RESEARCH 20
2.2.1.1 Key data from secondary sources 20
2.2.2 PRIMARY RESEARCH 21
2.2.2.1 Key data from primary sources 23
2.2.2.2 Key insights from primary sources 23
2.2.2.3 Key industry insights 24
2.3 MARKET SIZE ESTIMATION METHODOLOGY 24
2.4 MARKET DATA VALIDATION AND TRIANGULATION 27
2.5 ASSUMPTIONS FOR THE STUDY 28
3 EXECUTIVE SUMMARY 29
3.1 INTRODUCTION 29
3.2 CONCLUSION 32
4 PREMIUM INSIGHTS 33
4.1 PERFUSION SYSTEMS: MARKET OVERVIEW 33
4.2 GEOGRAPHIC ANALYSIS: PERFUSION SYSTEMS MARKET, BY TYPE (2016) 34
4.3 CELL PERFUSION SYSTEMS MARKET, BY TYPE, 2016 VS. 2021 35
4.4 GEOGRAPHIC SNAPSHOT OF THE PERFUSION SYSTEMS MARKET 35
5 MARKET OVERVIEW 36
5.1 INTRODUCTION 37
5.2 MARKET DYNAMICS 37
5.2.1 DRIVERS 38
5.2.1.1 Increasing prevalence of cardiovascular and respiratory diseases 38
5.2.1.2 Rising number of organ transplantations 38
5.2.1.2.1 Growth in aging population, increasing incidence of multiple organ failures 38
5.2.1.2.2 Government and NGO initiatives to encourage organ donation 38
5.2.1.3 Increasing investments in cell-based research 39
5.2.1.4 Increase in biologic manufacturing 39
5.2.2 RESTRAINTS 40
5.2.2.1 High cost of organ transplantation 40
5.2.2.2 Ethical concerns and high cost of cell-based research 40
5.2.3 OPPORTUNITIES 41
5.2.3.1 Increasing pharmaceutical research in emerging markets 41
5.2.3.2 Rising preference for continuous manufacturing 41
5.2.4 CHALLENGE 42
5.2.4.1 Organ supply-demand gap 42
6 CARDIOPULMONARY PERFUSION SYSTEMS MARKET, BY COMPONENT 43
6.1 INTRODUCTION 44
6.2 OXYGENATORS 44
6.3 HEART-LUNG MACHINES 45
6.4 PERFUSION PUMPS 46
6.5 CANNULAS 46
6.6 MONITORING SYSTEMS 47
6.7 OTHER COMPONENTS 47
6.7.1 ARTERIAL FILTERS 47
6.7.2 RESERVOIRS 47
6.7.3 DATA MANAGEMENT SYSTEMS 48
6.7.4 CARDIOPLEGIA DELIVERY SYSTEMS 48
6.7.5 HEAT EXCHANGERS 48
6.7.6 ACCESSORIES 48
7 CELL PERFUSION SYSTEMS MARKET, BY TYPE 49
7.1 INTRODUCTION 50
7.2 BIOREACTOR PERFUSION SYSTEMS 50
7.3 MICROFLUIDIC PERFUSION SYSTEMS 51
7.4 GRAVITY OR PRESSURE-DRIVEN PERFUSION SYSTEMS 51
7.5 SMALL-MAMMAL ORGAN PERFUSION SYSTEMS 52
8 EX VIVO ORGAN PERFUSION MARKET, BY TECHNIQUE 53
8.1 INTRODUCTION 54
8.2 HYPOTHERMIC MACHINE PERFUSION 54
8.3 NORMOTHERMIC MACHINE PERFUSION 56
?
9 GLOBAL PERFUSION SYSTEMS MARKET, BY REGION 57
9.1 INTRODUCTION 58
9.2 NORTH AMERICA 60
9.2.1 U.S. 62
9.2.1.1 Rise in cardiovascular disease prevalence 62
9.2.1.2 Technological Advancements in Organ Preservation 63
9.2.1.3 Increasing Organ Transplants 63
9.2.1.4 Introduction of the 21st Century Cures Act 63
9.2.1.5 Favorable Scenario for Cell Research, Growing Research Funding 64
9.2.1.6 Growth of the Pharmaceutical and Biotechnology Sector 64
9.2.2 CANADA 67
9.2.2.1 Increasing incidences of heart diseases 67
9.2.2.2 Favorable reimbursement scenario for living donors within some provinces 67
9.2.2.3 Increasing investment in regenerative medicine research projects 68
9.3 EUROPE 70
9.3.1 RAPIDLY AGING POPULATION, HIGH PREVALENCE OF CARDIOVASCULAR DISEASES IN EUROPE 70
9.3.2 EUROPE-5 73
9.3.2.1 Changes in organ donation laws in Wales 73
9.3.2.2 Strong academic and research base in Germany 73
9.3.2.3 Funding for research in the U.K. 74
9.3.2.4 Increasing cancer research in France 74
9.3.2.5 Italy: Growing biotech industry to aid market growth 74
9.3.3 ROE 76
9.3.3.1 Strong presence of pharmaceutical and biotechnology companies 76
9.3.3.2 Increasing research in Denmark and Sweden 77
9.4 ASIA-PACIFIC 79
9.4.1 INCREASING AGING POPULATION, RISE IN CARDIOVASCULAR SURGERY 79
9.4.2 JAPAN 82
9.4.2.1 Rising organ donations and transplants 82
9.4.2.2 Rise in vaccine production in Japan 82
9.4.2.3 Regenerative medicine and biomedical & medical research in Japan 83
9.4.3 CHINA 84
9.4.3.1 Regulatory framework for voluntary organ donations 84
9.4.3.2 Increasing government interest in biomedical and biotechnology industries 85
9.4.3.3 Growth of the pharmaceutical and biotechnology R&D industry and CROs sector 85
9.4.4 INDIA 87
9.4.4.1 Religious beliefs and lack of healthcare infrastructure in India 87
9.4.4.2 Growing pharmaceutical and biotechnology industry, government initiatives 87
9.4.5 REST OF ASIA-PACIFIC 89
9.4.5.1 Taiwan: Increasing government support for academic and commercial R&D 89
9.4.5.2 Establishment of R&D centers in Singapore 89
9.4.5.3 Korea-U.S. free trade agreement (KORUS) 90
9.5 REST OF THE WORLD 92
9.5.1.1 Campaigns to encourage organ donation in Brazil 92
9.5.1.2 Flourishing biotechnology and pharmaceutical markets in Brazil 92
9.5.1.3 Significant developments in the pharmaceutical market in Africa 92
9.5.1.4 Favorable regulatory environment in Saudi Arabia, Iran, and Israel 93
10 COMPETITIVE LANDSCAPE 97
10.1 INTRODUCTION 97
10.1.1 VANGUARDS 97
10.1.2 INNOVATOR 97
10.1.3 DYNAMIC 97
10.1.4 EMERGING 97
10.2 COMPETITIVE BENCHMARKING 99
10.2.1 PRODUCT OFFERINGS 99
10.2.2 BUSINESS STRATEGY 100
*Top 13 companies analyzed for this studies are - Getinge AB (Sweden), Medtronic plc (Ireland), Terumo Corporation (Japan), LivaNova PLC (U.K.), XENIOS AG (Germany), Repligen Corporation (U.S.), Spectrum Laboratories, Inc. (U.S.), Merck KGaA (Germany), Nipro Corporation (Japan), Harvard Bioscience, Inc. (U.S.), ALA Scientific Instruments, Inc. (U.S.), Lifeline Scientific, Inc. (U.S.), and XVIVO Perfusion AB (Sweden).
11 COMPANY PROFILE 101
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
11.1 GETINGE AB 101
11.2 MEDTRONIC PLC 104
11.3 LIVANOVA PLC 108
11.4 TERUMO CORPORATION 113
11.5 NIPRO CORPORATION 118
11.6 XENIOS AG (ACQUIRED BY FRESENIUS MEDICAL CARE AG & CO. KGAA) 121
11.7 REPLIGEN CORPORATION 124
11.8 SPECTRUM LABORATORIES, INC. 127
11.9 MERCK KGAA 129
11.10 HARVARD BIOSCIENCE, INC. 132
11.11 ALA SCIENTIFIC INSTRUMENTS, INC. 135
11.12 LIFELINE SCIENTIFIC, INC. (ORGAN RECOVERY SYSTEMS, INC.) 137
11.13 XVIVO PERFUSION AB 140
*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
12 APPENDIX 144
12.1 DISCUSSION GUIDE 144
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 147
12.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 149
12.3.1 FEATURES AND BENEFITS OF RT: 149
12.4 AVAILABLE CUSTOMIZATIONS 150
12.5 RELATED REPORTS 151
12.6 AUTHOR DETAILS 152
1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 17
1.3.1 MARKETS COVERED 17
1.3.2 YEARS CONSIDERED FOR THE STUDY 17
1.4 CURRENCY 18
1.5 LIMITATIONS 18
1.6 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH METHODOLOGY STEPS 19
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 20
2.2.1 SECONDARY RESEARCH 20
2.2.1.1 Key data from secondary sources 20
2.2.2 PRIMARY RESEARCH 21
2.2.2.1 Key data from primary sources 23
2.2.2.2 Key insights from primary sources 23
2.2.2.3 Key industry insights 24
2.3 MARKET SIZE ESTIMATION METHODOLOGY 24
2.4 MARKET DATA VALIDATION AND TRIANGULATION 27
2.5 ASSUMPTIONS FOR THE STUDY 28
3 EXECUTIVE SUMMARY 29
3.1 INTRODUCTION 29
3.2 CONCLUSION 32
4 PREMIUM INSIGHTS 33
4.1 PERFUSION SYSTEMS: MARKET OVERVIEW 33
4.2 GEOGRAPHIC ANALYSIS: PERFUSION SYSTEMS MARKET, BY TYPE (2016) 34
4.3 CELL PERFUSION SYSTEMS MARKET, BY TYPE, 2016 VS. 2021 35
4.4 GEOGRAPHIC SNAPSHOT OF THE PERFUSION SYSTEMS MARKET 35
5 MARKET OVERVIEW 36
5.1 INTRODUCTION 37
5.2 MARKET DYNAMICS 37
5.2.1 DRIVERS 38
5.2.1.1 Increasing prevalence of cardiovascular and respiratory diseases 38
5.2.1.2 Rising number of organ transplantations 38
5.2.1.2.1 Growth in aging population, increasing incidence of multiple organ failures 38
5.2.1.2.2 Government and NGO initiatives to encourage organ donation 38
5.2.1.3 Increasing investments in cell-based research 39
5.2.1.4 Increase in biologic manufacturing 39
5.2.2 RESTRAINTS 40
5.2.2.1 High cost of organ transplantation 40
5.2.2.2 Ethical concerns and high cost of cell-based research 40
5.2.3 OPPORTUNITIES 41
5.2.3.1 Increasing pharmaceutical research in emerging markets 41
5.2.3.2 Rising preference for continuous manufacturing 41
5.2.4 CHALLENGE 42
5.2.4.1 Organ supply-demand gap 42
6 CARDIOPULMONARY PERFUSION SYSTEMS MARKET, BY COMPONENT 43
6.1 INTRODUCTION 44
6.2 OXYGENATORS 44
6.3 HEART-LUNG MACHINES 45
6.4 PERFUSION PUMPS 46
6.5 CANNULAS 46
6.6 MONITORING SYSTEMS 47
6.7 OTHER COMPONENTS 47
6.7.1 ARTERIAL FILTERS 47
6.7.2 RESERVOIRS 47
6.7.3 DATA MANAGEMENT SYSTEMS 48
6.7.4 CARDIOPLEGIA DELIVERY SYSTEMS 48
6.7.5 HEAT EXCHANGERS 48
6.7.6 ACCESSORIES 48
7 CELL PERFUSION SYSTEMS MARKET, BY TYPE 49
7.1 INTRODUCTION 50
7.2 BIOREACTOR PERFUSION SYSTEMS 50
7.3 MICROFLUIDIC PERFUSION SYSTEMS 51
7.4 GRAVITY OR PRESSURE-DRIVEN PERFUSION SYSTEMS 51
7.5 SMALL-MAMMAL ORGAN PERFUSION SYSTEMS 52
8 EX VIVO ORGAN PERFUSION MARKET, BY TECHNIQUE 53
8.1 INTRODUCTION 54
8.2 HYPOTHERMIC MACHINE PERFUSION 54
8.3 NORMOTHERMIC MACHINE PERFUSION 56
?
9 GLOBAL PERFUSION SYSTEMS MARKET, BY REGION 57
9.1 INTRODUCTION 58
9.2 NORTH AMERICA 60
9.2.1 U.S. 62
9.2.1.1 Rise in cardiovascular disease prevalence 62
9.2.1.2 Technological Advancements in Organ Preservation 63
9.2.1.3 Increasing Organ Transplants 63
9.2.1.4 Introduction of the 21st Century Cures Act 63
9.2.1.5 Favorable Scenario for Cell Research, Growing Research Funding 64
9.2.1.6 Growth of the Pharmaceutical and Biotechnology Sector 64
9.2.2 CANADA 67
9.2.2.1 Increasing incidences of heart diseases 67
9.2.2.2 Favorable reimbursement scenario for living donors within some provinces 67
9.2.2.3 Increasing investment in regenerative medicine research projects 68
9.3 EUROPE 70
9.3.1 RAPIDLY AGING POPULATION, HIGH PREVALENCE OF CARDIOVASCULAR DISEASES IN EUROPE 70
9.3.2 EUROPE-5 73
9.3.2.1 Changes in organ donation laws in Wales 73
9.3.2.2 Strong academic and research base in Germany 73
9.3.2.3 Funding for research in the U.K. 74
9.3.2.4 Increasing cancer research in France 74
9.3.2.5 Italy: Growing biotech industry to aid market growth 74
9.3.3 ROE 76
9.3.3.1 Strong presence of pharmaceutical and biotechnology companies 76
9.3.3.2 Increasing research in Denmark and Sweden 77
9.4 ASIA-PACIFIC 79
9.4.1 INCREASING AGING POPULATION, RISE IN CARDIOVASCULAR SURGERY 79
9.4.2 JAPAN 82
9.4.2.1 Rising organ donations and transplants 82
9.4.2.2 Rise in vaccine production in Japan 82
9.4.2.3 Regenerative medicine and biomedical & medical research in Japan 83
9.4.3 CHINA 84
9.4.3.1 Regulatory framework for voluntary organ donations 84
9.4.3.2 Increasing government interest in biomedical and biotechnology industries 85
9.4.3.3 Growth of the pharmaceutical and biotechnology R&D industry and CROs sector 85
9.4.4 INDIA 87
9.4.4.1 Religious beliefs and lack of healthcare infrastructure in India 87
9.4.4.2 Growing pharmaceutical and biotechnology industry, government initiatives 87
9.4.5 REST OF ASIA-PACIFIC 89
9.4.5.1 Taiwan: Increasing government support for academic and commercial R&D 89
9.4.5.2 Establishment of R&D centers in Singapore 89
9.4.5.3 Korea-U.S. free trade agreement (KORUS) 90
9.5 REST OF THE WORLD 92
9.5.1.1 Campaigns to encourage organ donation in Brazil 92
9.5.1.2 Flourishing biotechnology and pharmaceutical markets in Brazil 92
9.5.1.3 Significant developments in the pharmaceutical market in Africa 92
9.5.1.4 Favorable regulatory environment in Saudi Arabia, Iran, and Israel 93
10 COMPETITIVE LANDSCAPE 97
10.1 INTRODUCTION 97
10.1.1 VANGUARDS 97
10.1.2 INNOVATOR 97
10.1.3 DYNAMIC 97
10.1.4 EMERGING 97
10.2 COMPETITIVE BENCHMARKING 99
10.2.1 PRODUCT OFFERINGS 99
10.2.2 BUSINESS STRATEGY 100
*Top 13 companies analyzed for this studies are - Getinge AB (Sweden), Medtronic plc (Ireland), Terumo Corporation (Japan), LivaNova PLC (U.K.), XENIOS AG (Germany), Repligen Corporation (U.S.), Spectrum Laboratories, Inc. (U.S.), Merck KGaA (Germany), Nipro Corporation (Japan), Harvard Bioscience, Inc. (U.S.), ALA Scientific Instruments, Inc. (U.S.), Lifeline Scientific, Inc. (U.S.), and XVIVO Perfusion AB (Sweden).
11 COMPANY PROFILE 101
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
11.1 GETINGE AB 101
11.2 MEDTRONIC PLC 104
11.3 LIVANOVA PLC 108
11.4 TERUMO CORPORATION 113
11.5 NIPRO CORPORATION 118
11.6 XENIOS AG (ACQUIRED BY FRESENIUS MEDICAL CARE AG & CO. KGAA) 121
11.7 REPLIGEN CORPORATION 124
11.8 SPECTRUM LABORATORIES, INC. 127
11.9 MERCK KGAA 129
11.10 HARVARD BIOSCIENCE, INC. 132
11.11 ALA SCIENTIFIC INSTRUMENTS, INC. 135
11.12 LIFELINE SCIENTIFIC, INC. (ORGAN RECOVERY SYSTEMS, INC.) 137
11.13 XVIVO PERFUSION AB 140
*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
12 APPENDIX 144
12.1 DISCUSSION GUIDE 144
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 147
12.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 149
12.3.1 FEATURES AND BENEFITS OF RT: 149
12.4 AVAILABLE CUSTOMIZATIONS 150
12.5 RELATED REPORTS 151
12.6 AUTHOR DETAILS 152
